Group 1 - The company Shanghai Yizhong (688091.SH) announced a share buyback proposal initiated by its actual controller and chairman, Zhou Jinsong [1] - The total amount for the buyback will not be less than 30 million yuan (including) and not exceed 35 million yuan (including) [1] - The buyback price will not exceed 150% of the average trading price of the company's shares over the 30 trading days prior to the board's resolution [1] - The buyback period will be within three months from the date of the shareholders' meeting approval of the buyback plan [1]

Group 1 - The company announced a proposal for share repurchase by its actual controller and chairman, Zhou Jinsong, using self-owned or self-raised funds through the Shanghai Stock Exchange trading system [1] - The total amount for the share repurchase is set to be no less than RMB 30 million and no more than RMB 35 million [1] - The repurchase price will not exceed 150% of the average trading price of the company's stock over the 30 trading days prior to the board's resolution [1] Group 2 - The shares repurchased will be sold through centralized bidding after 12 months from the announcement of the repurchase results and share changes [1] - The specific implementation plan will be subject to review and approval by the company's board in accordance with relevant laws and regulations [1]

上海谊众公告，董事长周劲松提议以集中竞价方式回购公司部分股份。拟回购股份的资金总额为不低于 3000万元，不超过3500万元，资金来源为自有资金或自筹资金。回购价格不超过公司董事会通过回购决 议前30个交易日公司股票交易均价的150%。回购期限为股东大会审议通过本次回购方案之日起3个月 内。 ...

证券代码：688091 证券简称：上海谊众 公告编号：2025-033 上海谊众药业股份有限公司关于 召开 2025 年半年度科创板创新药行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 （二） 会议召开地点： 上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） （三） 会议召开方式：上证路演中心网络文字互动 三、 参加人员 董事长、总经理：周劲松 董事会秘书：方舟 财务总监：汤节节 独立董事：胡改蓉 重要内容提示： 上海谊众药业股份有限公司（以下简称"公司"）已于 2025 年 8 月 8 日披 露公司《2025 年半年度报告》，为便于广大投资者更全面深入地了解公司 2025 年半年度的经营成果和财务状况，公司计划于2025年9月16日下午15:00-17:00 召开 2025 年半年度科创板创新药行业集体业绩说明会，就投资者关心的问题进 行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年半年度的经营 成果及财 ...

Group 1 - Shanghai Yizhong's stock price increased by 1.08% on August 25, with a trading volume of 358 million yuan [1] - The financing buy-in amount for Shanghai Yizhong on the same day was 20.55 million yuan, while the financing repayment was 24.93 million yuan, resulting in a net financing outflow of 4.38 million yuan [1] - As of August 25, the total margin balance for Shanghai Yizhong was 532 million yuan, with the financing balance accounting for 3.51% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, the number of shareholders for Shanghai Yizhong was 6,521, an increase of 6.14% from the previous period [2] - The average circulating shares per person decreased by 5.78% to 31,698 shares [2] - For the first half of 2025, Shanghai Yizhong reported operating revenue of 160 million yuan, a year-on-year increase of 31.48%, and a net profit attributable to shareholders of 38.00 million yuan, up 10.13% year-on-year [2] Group 3 - Since its A-share listing, Shanghai Yizhong has distributed a total of 92.23 million yuan in dividends [3]

Group 1 - Shanghai Kaibao (300039) responded to investor inquiries on August 22 regarding the products and operational status of Shanghai Yizhong, directing investors to refer to Shanghai Yizhong's periodic reports [1]

证券之星消息，8月19日化学制药板块较上一交易日下跌0.66%，上海谊众领跌。当日上证指数报收于 3727.29，下跌0.02%。深证成指报收于11821.63，下跌0.12%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603520 | 司太立 | 12.16 | 10.05% | 22.82万 | | 2.69亿 | | 603811 | 诚意药业 | 16.82 | 10.01% | 31.23万 | | 5.14亿 | | 003020 | 立方制药 | 37.00 | 9.99% | 8.94万 | | 3.23亿 | | 002940 | 昂利康 | 54.86 | 8.63% | 25.65万 | | 13.73亿 | | 300016 | 北陆药业 | 11.26 | 7.44% | 130.35万 | | 14.77亿 | | 600513 | 联环药业 | 29.47 | 6.08% | 61.98万 | | 18.12亿 | ...

Group 1 - The A-share market has seen a decline in several biopharmaceutical stocks, with notable drops including Nanmo Bio down 9%, Shanghai Yizhong down over 7%, and Nuocheng Jianhua down over 5% [1] - Other companies experiencing declines include Yangguang Nuohuo and Guangshengtang down over 4%, and Haichuang Pharmaceutical, Baicheng Pharmaceutical, Yaokang Bio, and Qianyan Bio down over 3% [1] Group 2 - Specific stock performance includes: - Nanmo Bio (688265) down 9.06% with a market cap of 5.027 billion and a year-to-date increase of 178.89% - Shanghai Yizhong (688091) down 7.23% with a market cap of 15.7 billion and a year-to-date increase of 89.98% - Nuocheng Jianhua (688428) down 5.25% with a market cap of 56 billion and a year-to-date increase of 158.55% - Yangguang Nuohuo (688621) down 4.57% with a market cap of 8.727 billion and a year-to-date increase of 107.29% - Guangshengtang (300436) down 4.26% with a market cap of 26.3 billion and a year-to-date increase of 404.68% [2]

Group 1 - A-share market sees weakness in certain biopharmaceutical stocks, with notable declines in several companies [1] - Nanmo Bio falls by 9%, while Shanghai Yizhong drops over 7% [1] - Nocare Health declines by over 5%, and Sunshine Nuohe and Guangshengtang both decrease by over 4% [1] - Haichuang Pharmaceutical, Baicheng Pharmaceutical, Yaokang Bio, and Qianyan Bio all experience declines of over 3% [1]

Core Viewpoint - The pharmaceutical sector has shown significant stock price increases, with several companies experiencing notable gains in their share prices recently [1][2]. Group 1: Stock Performance - Hanyu Pharmaceutical (300199) saw a rise of 12.05%, with a total market capitalization of 25.8 billion [2]. - Wanbangde (002082) achieved a 10.01% increase, with a market cap of 4.906 billion [2]. - Tianshili (600535) increased by 7.73%, with a market value of 26 billion [2]. - Shanghai Yizhong (688091) rose by 6.94%, with a market cap of 16.9 billion [2]. - Olin Bio (688319) and Sunshine Nuohe (688621) both increased by over 5%, with market caps of 10.3 billion and 9.033 billion respectively [2]. - Other companies like Nuo Silan De (430047), Haita Bio (300683), and Nanxin Pharmaceutical (688189) also reported gains of over 4% [2]. Group 2: Year-to-Date Performance - Hanyu Pharmaceutical (300199) has shown a year-to-date increase of 126.53% [2]. - Olin Bio (688319) and Sunshine Nuohe (688621) have year-to-date increases of 139.06% and 114.56% respectively [2]. - Haita Bio (300683) and Nanxin Pharmaceutical (688189) also reported significant year-to-date increases of 143.08% and 114.53% respectively [2].